2A Pharma

The story of the technology behind our company started in 2005 when John Nieland, then Head of Immunology at Medigene AG, and colleagues Markus Hörer and Hildegard Büning discovered how to replace the peptides on the surface of a modified adeno virus with antigens to induce and enhance the specific antibody immune response. The AAVLP inventions were patented in the following years, but the potential was never commercialised as Medigene focused on other projects and John Nieland left the company to pursue new opportunities. In 2014 John Nieland joined Professor Søren Nielsen at Aalborg University and the idea to develop a company around AAVLP was again ignited. John Nieland and Søren Nielsen approached Medigene with their idea and started the discussions about an in-licensing agreement while also exploring funding options. During this process, the team was expanded to include Preben Bruun-Nyzell. 2A Pharma AB was founded on 12 December 2016 in Malmö, Sweden. Shortly thereafter, the company’s first employee, Jeanette Prangsgaard, joined as Project Manager for our lead project.